Abstract Library

Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.

Participants of the ENETS Conference in 2023 can now access the abstract booklet, e-posters and videos, the poster carousel, and more via My ENETS.

ENETS Abstract Search

#3079 Novel Symptoms and Therapy of Multiple Endocrine Neoplasia Type 1

Introduction: MEN1 is a rare autosomal inherited disease with hallmark of hyperparathyroidism, duodenopancreatic NENs and pituitary tumor.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: bai J

Authors: Bai J, Tang Q,

Keywords: MEN1, LGCS, NENs, gastrinoma, Parathyroid carcinoma,

#3038 Managing Neuroendocrine Neoplasms (NEN) in Association with HIV Infection: A Single Institution Experience

Introduction: There is a paucity of knowledge regarding NEN and HIV infection in the literature.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Hayes A, Smith K, Liu M, Jenkinson S, Grossman A,

Keywords: Neuroendocrine, Carcinoid, Merkel cell carcinoma, Human immunodeficiency virus, HIV, Prognosis,

#3030 Targeting CXCR4 and Thioredoxin Reductase in Theranostics of Atypical Carcinoid and Neuroendocrine Carcinoma

Introduction: Atypical carcinoid and small cell lung cancer (SCLC) are currently incurable. There is thus a critical need for new diagnostic and therapeutic strategies for lung neuroendocrine neoplasms (LNEN). Chemokine receptor 4 (CXCR4), a G protein coupled receptor and theranostic target, plays a crucial role in metastases of LNEN. We hypothesize combination of thioredoxin reductase (TR) inhibitor represents a metabolic strategy to enhance cytotoxicity in peptide-receptor radionuclide therapy (PRRT) of LNEN.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Liu D

Authors: Liu D, Fath M, Robles Planells C, Balk E, Bellizzi A,

Keywords: CXCR4, thioredoxin reductase inhibitor, theranostics, atypical carcinoid, small cell lung cancer,

#3022 Diagnostic Accuracy of 68Gallium Positron Emission Tomography (68Ga PET), Endoscopic Ultrasound (EUS) and Computed Tomography in the Assessment of Lymphnode Metastases by Nonfunctioning Pancreatic Neuroendocrine Neoplasms

Introduction: The presence of nodal metastasis is one of the most important predictive factors for recurrence after radical surgery for nonfunctioning Pancreatic Neuroendocrine Neoplasms (NF-PanNEN). Nevertheless, it is not clear which is the best diagnostic examination to identify preoperatively lymphnodal metastasis.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Giannone F

Authors: Giannone F, Muffatti F, Partelli S, Andreasi V, Guarneri G,

Keywords: imaging, lymph node, metastases,

#3013 Structurally-Optimized Peptide VMT-Alpha-NET Enhances the Efficacy of SSTR2-Targeted Alpha-Particle Therapy for Neuroendocrine Tumors

Introduction: 203Pb/212Pb is a promising theranostics pair for SSTR2-targeted alpha-particle therapy for neuroendocrine tumors (NETs). The development of SSTR2-targeted peptides that are optimized for the Pb isotopes has the potential to improve performance.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Lee D, Li M, Baumhover N, Liu D, Sagastume E,

Keywords: prrt, VMT-alpha-NET, 203Pb/212Pb theranostics,

Abstract Submissions in 2023

Abstract submissions for 2024 will open in September 2023!

 

The 21st Annual ENETS Conference in 2024 will provide the principal platform for NET researchers around the world to present their latest findings. ENETS will select the best abstracts submitted in both clinical and basic science and present these in sessions within the framework of its scientific programme.

 

Participants of the ENETS Conferences in 2023 can now access the abstract booklet, e-posters and videos, the poster carousel, and more via My ENETS.

Membership matters

Multidisciplinary is our credo. We welcome all NET-related disciplines and professionals! Learn more about the benefits of becoming an ENETS member.